• EOFlow publishes the final report on its first clinical trial

  • On December 3, 2020, EOFlow announces that it has received the final report on the post-market clinical study on EOPatch wearable insulin pump system, conducted in Korea over the summer this year.  The study was conducted on 9 patients over a month's time and it showed significant improvement on TIR (Time in Range), with subject patients staying within the target blood glucose range (70~180mg/dL) much longer, and having significantly less incidents of severe hypoglycemic events (<54mg/dL).  7 patients out of 9 had expressed their satisfaction with the ease of use, and 8 out of 9 had expressed satisfaction on the aspect of life quality improvement.  This was the very first official clinical study conducted with EOFlow's EOPatch wearable insulin pump system.

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here